BioTime, Inc. (BTX) Stake Held by California Public Employees Retirement System

California Public Employees Retirement System held its stake in shares of BioTime, Inc. (NYSEAMERICAN:BTX) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 48,400 shares of the biotechnology company’s stock at the end of the 2nd quarter. California Public Employees Retirement System’s holdings in BioTime were worth $152,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. American International Group Inc. lifted its position in BioTime by 8.3% during the 1st quarter. American International Group Inc. now owns 39,794 shares of the biotechnology company’s stock worth $137,000 after buying an additional 3,036 shares in the last quarter. Ameriprise Financial Inc. bought a new stake in BioTime during the 2nd quarter worth about $142,000. State of Wisconsin Investment Board bought a new stake in BioTime during the 2nd quarter worth about $180,000. Metropolitan Life Insurance Co. NY lifted its position in BioTime by 14.7% during the 1st quarter. Metropolitan Life Insurance Co. NY now owns 57,694 shares of the biotechnology company’s stock worth $199,000 after buying an additional 7,411 shares in the last quarter. Finally, Nationwide Fund Advisors lifted its position in BioTime by 61.2% during the 2nd quarter. Nationwide Fund Advisors now owns 71,857 shares of the biotechnology company’s stock worth $226,000 after buying an additional 27,279 shares in the last quarter.

BTX has been the topic of several recent analyst reports. Zacks Investment Research lowered shares of BioTime from a “hold” rating to a “sell” rating in a research note on Friday, October 20th. BidaskClub lowered shares of BioTime from a “sell” rating to a “strong sell” rating in a research note on Wednesday, October 18th. Two equities research analysts have rated the stock with a sell rating and three have issued a buy rating to the company’s stock. BioTime currently has a consensus rating of “Hold” and a consensus price target of $5.08.

In other news, Director Broadwood Partners, L.P. acquired 2,692,307 shares of the stock in a transaction dated Friday, October 13th. The shares were bought at an average cost of $2.60 per share, for a total transaction of $6,999,998.20. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

BioTime, Inc. (NYSEAMERICAN:BTX) traded down $0.12 during trading on Friday, hitting $2.56. 523,880 shares of the stock traded hands, compared to its average volume of 368,459. BioTime, Inc. has a one year low of $2.19 and a one year high of $3.96.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.com-unik.info/2017/12/03/biotime-inc-btx-stake-held-by-california-public-employees-retirement-system.html.

About BioTime

BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.

Want to see what other hedge funds are holding BTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTime, Inc. (NYSEAMERICAN:BTX).

Institutional Ownership by Quarter for BioTime (NYSEAMERICAN:BTX)

What are top analysts saying about BioTime Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BioTime Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit